Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Monopar Therapeutics MNPR

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
$-13.7M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 0.00
Revenue, FY2025 · full 10-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -13.7
-10M-20M
2016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE
FY2025 · ROE -14.2%
-100%-200%
201620202025
Three returns, three denominators.

Each USD of equity lost 14 cents this year.

Cash & shareholders

USD 35.0M
returned in FY2025 · dividends + net buybacks
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 35.0
15M30M-2M-3M
20242025

USD 35.0M in buybacks went back to shareholders in a year without profit.

Total assetsUSD 140.7M
EquityUSD 137.8M
CashUSD 61.8M
Current ratio51.35×

Equity funds 98% of total assets.

The 10-year record

10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
MNPR, 10-year financial record
Metric 2025202420232022202120202019201820172016
Revenue $B0.00.0◌◌◌◌0.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B◌◌◌◌◌◌◌◌◌◌
Income tax $B0.00.00.00.00.00.00.0−0.0−0.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $◌◌◌◌−0.73−0.58−0.45−0.35−1.89◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————
ROE %−14.2−51.4−107.2−72.4−52.6−44.5−43.2−39.0−265.9−41.9
Shares out B0.010.010.010.010.010.010.010.010.010.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 39 reconciliationsAUDITED

Reconciled in 10 of the 10 fiscal years we could check. 18 checks were skipped: the balance sheet is not tagged before 2016. 10 checks were skipped: EPS is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2016

Share this section

Download image